Holen Sie sich die Stockscreener-App
12.37
1.12%
-0.14
Handel nachbörslich:
12.37
Schlusskurs vom Vortag:
$12.51
Offen:
$12.59
24-Stunden-Volumen:
320.35K
Relative Volume:
0.63
Marktkapitalisierung:
$907.98M
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-8.1921
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
-2.75%
1M Leistung:
-7.27%
6M Leistung:
-0.40%
1J Leistung:
+17.59%
1-Tages-Spanne:
$12.20
$12.64
1-Wochen-Bereich:
$12.15
$13.28
52-Wochen-Spanne:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Vergleichen Sie ZYME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
12.37 | 907.98M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Ecor1 Capital’s Oleg Nodelman buys $1.23 million in Zymeworks stock By Investing.com - Investing.com Canada
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Biotech Zymeworks Reveals New Pipeline Insights at Two Major Healthcare Conferences - StockTitan
Zymeworks to Present Promising Cancer Therapy Data at AACR Meeting - TipRanks
Zymeworks to Present Preclinical Data on T cell Engager and - GlobeNewswire
Game-Changing Cancer Drug Results: Zymeworks Reveals 6 Promising Treatments at AACR - StockTitan
Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus.com
Zymeworks Inc. sees $1.64 million stock purchase by EcoR1 Capital - Investing.com Philippines
EcoR1 Capital, LLC's Strategic Acquisition of Zymeworks Inc Shar - GuruFocus.com
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Zymeworks sees over $2.8 million in stock purchases by EcoR1 Capital - Investing.com Australia
Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from Brokerages - Defense World
Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital - Defense World
EcoR1 capital acquires $13.1 million in Zymeworks stock By Investing.com - Investing.com South Africa
EcoR1 capital acquires $13.1 million in Zymeworks stock - Investing.com India
Equities Analysts Issue Forecasts for Zymeworks Q1 Earnings - Defense World
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock? - Nasdaq
Zymeworks (NYSE:ZYME) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Zymeworks (ZYME) with Outperform Recommendation - Nasdaq
Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 13% - Simply Wall St
Zymeworks (NYSE:ZYME) Price Target Raised to $13.00 at HC Wainwright - Defense World
Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings) - Benzinga
Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates - Yahoo Finance
Citigroup Boosts Zymeworks (NYSE:ZYME) Price Target to $19.00 - Defense World
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 - Benzinga India
Zymeworks Inc. (NYSE:ZYME) Q4 2024 Earnings Call Transcript - Insider Monkey
Zymeworks Inc (ZYME) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights - Yahoo Finance
Zymeworks Inc (ZYME) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights By GuruFocus - Investing.com Canada
Zymeworks Reports 2024 Financial Results and Pipeline Progress - TipRanks
Zymeworks Achieves FDA Approval for Ziihera® - TipRanks
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates - MSN
Zymeworks Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Zymeworks Q4 2024 sees modest revenue, stock dips - Investing.com UK
Zymeworks Q4 Net Loss Widens, Revenue Increases; Shares Fall After Hours -March 05, 2025 at 04:55 pm EST - Marketscreener.com
Zymeworks Inc Q4 2024 Earnings: EPS of -$0.31 and Revenue of $31 - GuruFocus.com
Zymeworks shares fall as Q4 earnings miss expectations By Investing.com - Investing.com Canada
Zymeworks shares fall as Q4 earnings miss expectations - Investing.com India
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
How Will Zymeworks' FDA Win for Ziihera Impact Its $122M Annual Loss? - StockTitan
Rhumbline Advisers Buys 15,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Inc (ZYME) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Zymeworks (ZYME) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Zymeworks Inc.'s (NASDAQ:ZYME) Business Is Yet to Catch Up With Its Share Price - Simply Wall St
Zymeworks Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsZYME - ACCESS Newswire
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration - Wahanariau
Zymeworks Achieves $14 Million in Milestone Payment From GSK Partnership -February 26, 2025 at 09:06 am EST - Marketscreener.com
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):